<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39348666</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Informatics and Artificial Intelligence-Guided Assessment of the Regulatory and Translational Research Landscape of First-in-Class Oncology Drugs in the United States, 2018-2022.</ArticleTitle><Pagination><StartPage>e2400087</StartPage><MedlinePgn>e2400087</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI.24.00087</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cancer drug development remains a critical but challenging process that affects millions of patients and their families. Using biomedical informatics and artificial intelligence (AI) approaches, we assessed the regulatory and translational research landscape defining successful first-in-class drugs for patients with cancer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a retrospective observational study of all novel first-in-class drugs approved by the US Food and Drug Administration (FDA) from 2018 to 2022, stratified by cancer versus noncancer drugs. A biomedical informatics pipeline leveraging interoperability standards and ChatGPT performed integration and analysis of public databases provided by the FDA, National Institutes of Health, and WHO.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Between 2018 and 2022, the FDA approved a total of 247 novel drugs, of which 107 (43.3%) were first-in-class drugs involving a new biologic target. Of these first-in-class drugs, 30 (28%) treatments were indicated for patients with cancer, including 19 (63.3%) for solid tumors and the remaining 11 (36.7%) for hematologic cancers. A median of 68 publications of basic, clinical, and other relevant translational science preceded successful FDA approval of first-in-class cancer drugs, with oncology-related treatments involving fewer median years of target-based research than therapies not related to cancer (33 <i>v</i> 43 years; <i>P</i> &lt; .05). Overall, 94.4% of first-in-class drugs had at least 25 years of target-related research papers, while 85.5% of first-in-class drugs had at least 10 years of translational research publications.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Novel first-in-class cancer treatments are defined by diverse clinical indications, personalized molecular targets, dependence on expedited regulatory pathways, and translational research metrics reflecting this complex landscape. Biomedical informatics and AI provide scalable, data-driven ways to assess and even address important challenges in the drug development pipeline.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ronquillo</LastName><ForeName>Jay G</ForeName><Initials>JG</Initials><Identifier Source="ORCID">0000-0002-0438-7172</Identifier><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pfizer Research and Development, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>South</LastName><ForeName>Brett</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pfizer Research and Development, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naik</LastName><ForeName>Prakash</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pfizer Research and Development, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Rominder</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0001-8298-8176</Identifier><AffiliationInfo><Affiliation>Pfizer Research and Development, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jesus</LastName><ForeName>Magdia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pfizer Research and Development, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watt</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pfizer Research and Development, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habtezion</LastName><ForeName>Aida</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pfizer Research and Development, Pfizer Inc, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057170" MajorTopicYN="Y">Translational Research, Biomedical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014486" MajorTopicYN="Y">United States Food and Drug Administration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="Y">Drug Approval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="N">Medical Informatics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39348666</ArticleId><ArticleId IdType="doi">10.1200/CCI.24.00087</ArticleId></ArticleIdList></PubmedData></PubmedArticle>